AU2018280340A1 - A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a RANK-L (NF-κΒ ligand) antagonist for cancer therapy or prophylaxis and uses therefor. - Google Patents

A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a RANK-L (NF-κΒ ligand) antagonist for cancer therapy or prophylaxis and uses therefor. Download PDF

Info

Publication number
AU2018280340A1
AU2018280340A1 AU2018280340A AU2018280340A AU2018280340A1 AU 2018280340 A1 AU2018280340 A1 AU 2018280340A1 AU 2018280340 A AU2018280340 A AU 2018280340A AU 2018280340 A AU2018280340 A AU 2018280340A AU 2018280340 A1 AU2018280340 A1 AU 2018280340A1
Authority
AU
Australia
Prior art keywords
seq
antigen
binding molecule
polypeptide
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018280340A
Other languages
English (en)
Inventor
Elizabeth AHERN
Bill DOUGALL
Mark Smyth
Michele TENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902125A external-priority patent/AU2017902125A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of AU2018280340A1 publication Critical patent/AU2018280340A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018280340A 2017-06-05 2018-06-05 A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a RANK-L (NF-κΒ ligand) antagonist for cancer therapy or prophylaxis and uses therefor. Abandoned AU2018280340A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902125A AU2017902125A0 (en) 2017-06-05 "Agents for cancer therapy or prophylaxis and uses therefor"
AU2017902125 2017-06-05
PCT/AU2018/050557 WO2018223182A1 (en) 2017-06-05 2018-06-05 A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor.

Publications (1)

Publication Number Publication Date
AU2018280340A1 true AU2018280340A1 (en) 2019-12-19

Family

ID=64565634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018280340A Abandoned AU2018280340A1 (en) 2017-06-05 2018-06-05 A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a RANK-L (NF-κΒ ligand) antagonist for cancer therapy or prophylaxis and uses therefor.

Country Status (7)

Country Link
US (1) US20230042913A1 (https=)
EP (1) EP3634484A4 (https=)
JP (1) JP2020522529A (https=)
CN (1) CN111032085A (https=)
AU (1) AU2018280340A1 (https=)
CA (1) CA3065836A1 (https=)
WO (1) WO2018223182A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
CA3121945A1 (en) * 2018-12-05 2020-06-11 The Council Of The Queensland Institute Of Medical Research Rank antagonists and uses therefor
EP3906415B1 (en) * 2019-01-03 2026-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
CN110179977A (zh) * 2019-05-22 2019-08-30 华中科技大学同济医学院附属同济医院 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂
KR20220034117A (ko) * 2019-06-14 2022-03-17 더 스크립스 리서치 인스티튜트 면역 관문 차단 이중특이성 분자
WO2021013068A1 (en) * 2019-07-19 2021-01-28 Wuxi Biologics (Shanghai) Co., Ltd. Polypeptide complex for conjugation and use thereof
CN110938652A (zh) * 2019-11-07 2020-03-31 浙江大学医学院附属第一医院 打靶载体及构建白喉毒素调控清除巨噬细胞的f4/80-dtr转基因小鼠的方法和应用
WO2021115465A1 (en) * 2019-12-13 2021-06-17 Biosion Inc. Antibodies binding rankl and uses thereof
MY202559A (en) * 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
SE544000C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein
SE544001C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody
CN111808198B (zh) * 2020-07-27 2022-06-03 广东安普泽生物医药股份有限公司 一种特异性结合rankl靶向治疗药物的抗体及其应用
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
CN115466328B (zh) * 2021-06-11 2025-09-12 广东菲鹏制药股份有限公司 抗pd-1人源化抗体或其抗原结合片段及其应用
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
KR20240039005A (ko) * 2021-07-28 2024-03-26 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 다중-특이적 분자
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
AU2023347288A1 (en) 2022-09-23 2025-03-13 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma
WO2024104409A1 (zh) * 2022-11-16 2024-05-23 苏州盛迪亚生物医药有限公司 一种含抗rankl-ngf双特异性抗体的药物组合物
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer
WO2024149237A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
TW202525857A (zh) * 2023-09-11 2025-07-01 大陸商上海才致藥成生物科技有限公司 長效副甲狀腺激素受體促效劑融合蛋白及其應用
WO2025245693A1 (zh) * 2024-05-28 2025-12-04 北京量觉科技有限责任公司 免疫相关不良反应生物标志物及试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
CN104861067A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
RU2767329C2 (ru) * 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
DE102017110958A1 (de) * 2016-05-20 2017-11-23 Christoph Karl Pharmazeutische Zusammensetzungen mit Anti-RANKL-Antikörpern, Kalzium und Vitamin D, geeignet zur Behandlung und/oder Prophylaxe von Erkrankungen des Knochenstoffwechsels und von therapiebedingten Hypokalzämien
JP2019528305A (ja) * 2016-08-25 2019-10-10 エイアイ・セラピューティクス・インコーポレーテッド ＰＩＫｆｙｖｅ阻害薬を含む組成物およびＲＡＮＫシグナル伝達の阻害に関連する方法

Also Published As

Publication number Publication date
JP2020522529A (ja) 2020-07-30
WO2018223182A1 (en) 2018-12-13
CN111032085A (zh) 2020-04-17
EP3634484A4 (en) 2022-01-12
EP3634484A1 (en) 2020-04-15
CA3065836A1 (en) 2018-12-13
US20230042913A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
US20230042913A1 (en) A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof
US11746157B2 (en) PSMA binding agents and uses thereof
TWI772275B (zh) 特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
DK3097121T3 (en) ANTIBODY MOLECULES AGAINST PD-1 AND APPLICATIONS THEREOF
US11066471B2 (en) Antibodies to MICA and MICB proteins
AU2018260505A1 (en) Antibody conjugates comprising toll-like receptor agonist and combination therapies
CN108137691A (zh) 特异性针对人类t-细胞免疫球蛋白和itim结构域（tigit）的抗体
US20220227876A1 (en) Rank antagonists and uses thereof
WO2017040660A1 (en) Combination therapy for treatment of disease
WO2021079958A1 (ja) 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ
US20240166759A1 (en) Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
EA046641B1 (ru) Агенты, связывающиеся с psma, и виды их применения

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application